• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Switzerland·Financial Services·BBN.SW
Share

Bellevue Group AG Stocks

CHF 6.6Last Updated 22.10.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Moderate

Recommendation

Hold

Market Cap

CHF 109.29M

CHF 6.6
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Bellevue Group AG operates as an asset management specialist with a presence spanning Switzerland, the United Kingdom, Germany, and additional international markets. The firm's product portfolio encompasses distinctive healthcare equity offerings, meticulously chosen niche investment opportunities, and strategies tailored for entrepreneurial ventures. It also oversees a diverse array of investment funds and crafts bespoke investment solutions for its institutional, intermediary, and individual clientele, further providing comprehensive investment advisory and research capabilities. Established in 1993, its principal offices are located in Küsnacht, Switzerland.

Company Valuation

Undervalued
6/7

Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is reasonably priced on P/E, 'cheap' on EV/EBITDA

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

23.10.2026 20:18

Not all AI stocks are equally resilient: Morgan Stanley has selected 24 favorites

23.10.2026 19:28

Apple surpassed Nvidia during trading and became the world's most valuable company

23.10.2026 18:44

U.S. equities slide at the open on Friday as Brent crude tops $115

23.10.2026 18:36

Jensen Huang: “Today, I’m even more enthusiastic about AI than I was a year ago.”

23.10.2026 17:55

Biohaven soars 25% as drug moves closer to approval. Is there more upside?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026